Under the partnership, a fully cGMP-compliant analytical testing facility will be developed in Shanghai in 25,000-square-foot area by WuXi which will build, equip and operate the facility. Stability samples will be stored and tested in the facility where other services will also be provided for Bristol-Myers.
WuXi will provide analytical testing, metrology, pharmaceutical science, quality assurance, sample management, stability testing and stability data reporting for global dossier submissions by Bristol-Myers.
WuXi PharmaTech chairman and CEO Ge Li said the company will continue to help Bristol-Myers to improve its R&D productivity with innovation-driven, cost-effective and fully integrated R&D service platform.
Bristol-Myers Squibb Non-Clinical Development senior vice president Mark Powell said the partnership will expand the relationship with WuXi and strengthens its presence in China.